COVID-19 UPDATE: White House announces alliances to vastly expand testing in next month (8mm/month, Federal). And rising opportunity cost of being "undecided" as S&P 500 100 points higher than 50% retrace.

COVID-19 remains a global crisis and we realize that many people need to keep up with COVID-19 developments, particularly since we are moving into the more critical stage ("restart economy"), so feel free to share our commentary to anyone who has interest.


The White House briefing focused on the rapid expansion of testing capacity underway in the US.  According to Admiral Giroir (designated to coordinate COVID-19 testing), the US will be able to conduct 8 million tests per month (federal level) by next month with Abbott Labs, LabCorp, Quest Diagnostics providing additional testing. In short, the US is on track to conduct 500k-750k tests per day (with private sector additions).  For policymakers, and especially state governors (the NGA), this is a key gating factor to getting the economy open. Whether testing is the key factor, that doesn't matter, since it matters to policymakers.

But the broad picture is that the US private sector and policymakers have mobilized in a huge way to deal with COVID-19.  And states are mostly showing improvements.  As of today, 20 states have announced plans to re-open their economies in the next few weeks, with West Virginia being the most recent to announce. These states are 33% of US GDP and the largest of these states is Texas.  By our analysis, 6 of these 20 have shown sustained and pervasive improvements in case count (see below) but this doesn't mean the other 14 states are not correct to open.  Rather, we believe there are actually another 11 states that should be added to the 20 already -- meaning as many as 31 states should consider opening in the next few weeks. This excludes NY state.

On the healthcare side, NY Gov. Cuomo announced the results of a second serological study (this time 7,500 tests) and shows prevalence 10X official estimates and affirms mortality for NY state is 0.56% or so, way less deadly than the 5%-10% seen in official stats.

The rising opportunity cost of being "undecided" or "sidelined" on stocks...
The stock market, in the meantime, remains resilient, closing 100 points the critical 50% retrace line (2,793) and in the face of a healthy high-yield market, argues that equities have upside.  This despite what we sense as widespread "uncertainty" about equities and thus, many investors remain sidelined or "undecided." 

The past 4 weeks has been the most devastating gauntlet for equities -->
- COVID-19 pandemic,
- World economy shuts down, 
- OPEC blows up,
- worst GDP print since the Great Depression,
- 6mm unemployed claims,
- WTI near contract goes negative at -$48 per barrel (how does that happen?)
- 1Q2020 EPS missing by 20%

Yet, the S&P 500 has managed to claw back >50% of its losses and NASDAQ is now up YTD.  This resilience is telling that the consensus narrative of "economy gonna tank so gets out of stocks" is overly pessimistic.  And as we highlight at the end of this note, there are positive tailwinds building as we move into May.  We realize many investors were understandably expecting a "retest" of the March 2020 lows and potentially break below 2,200 towards 1,700.  This could happen, but is there another gauntlet of headwinds worse than what we saw in the past 4 weeks? If not, we think it less likely to retest the lows.


POINT #1: NY announces 2nd serological study affirms prevalence 10X the "official estimate" -- NYC est. 25% prevalence.  Why is NYC still closed?
Gov Cuomo in his press briefing today announced the results of the second serological study (using antibodies).  This second study is expanded with 7,500 participants and is also conducted 1 week after the first study (results are announced two weeks after the testing completed).  The results are consistent with the first study:

- NY state overall is estimated to have 15% of the population (+100bp from 13.9% prior study) and is 10X the official rate.
- NYC is now estimated to be 24.7% from 21.2% or up 350bp in the period between the studies.  This again is 13X the official rate.
- 6 of 6 studies (below) show that using anti-body studies, the prevalence of COVID-19 is 10X to 50X to 85X greater than realized.

As noted previously, this has big implications for understanding disease severity (most are therefore showing no symptoms) and the lower "death rate" as the number of cases is vastly higher. And we also think this suggests policy options should change, with treatment > vaccine and treatment arguably > testing.  

checkout-thomas-lee image
checkout-logo image

Become a Member To Access FS Insight Research

FS Insight gives individual investors access to Tom Lee's research, previously only available to banks and hedge funds.

Monthly

$199/mo

Includes 30-Day Free Trial

Join Now

Annual

-15% $2,028/yr

List Price: $2,388

Savings: $360

Join Now

What's included in your FSI Membership?

tom lee iamge

Thomas J. Lee

Head of Research

Type Publication Mon Tue Wed Thu Fri Monthly
Reports First Word
The best market research out there -- on a near-daily basis.
Intraday Alerts
These are released periodically after crucial market developments.
Real-Time
Weekly Roadmap
Weekly summary of market events and updates on our key theses.
Webinars & Videos Macro Minute Video
Daily video commentary on market conditions & key events.
Outlook Webinars
We host over 12 LIVE webinars per year with our research team and high-profile special guests. Incredible value and market insights!
Yearly
Granny Shots Webinars
CEO Interview Webinars Quarterly
Appearances Archive Real-Time
Allocation Tools "Super Granny" Shots Stock List
Granny Shots we expect to tactically outperform and underperform.
Granny Shots Stock List
Thematic investment stock picks that aim to outperform the S&P 500.
Sector Allocation
A sector allocation strategy that is designed to outperform the S&P 500 while taking minimal risk.
Market Alerts ⚡️FlashInsights
Real-time market commentary about macro and crypto events from our research heads.
Real-Time
tom lee iamge

Mark L. Newton

Head of Technical Strategy

Type Publication Mon Tue Wed Thu Fri Monthly
Reports Daily Technical Strategy
Daily commentary on market trends and short term opportunities.
Weekly Roadmap
Weekly summary of market events and updates on our key theses.
Webinars & Videos Daily Technical Strategy
Daily commentary on market trends and short term opportunities.
Live Technical Analysis
Outlook Webinars
We host over 12 LIVE webinars per year with our research team and high-profile special guests. Incredible value and market insights!
Yearly
Appearances Archive Real-Time
Allocation Tools Newton's Upticks Stock List
Technically derived, intermediate-term picks of attractive risk/reward opportunities from the S&P 500.
Market Alerts ⚡️FlashInsights
Real-time market commentary about macro and crypto events from our research heads.
tom lee iamge

L. Thomas Block

Washington Policy Strategy

Type Publication Mon Tue Wed Thu Fri Monthly
Reports US Policy
Weekly update on developments in Washington DC and how they may impact Wall Street.
Weekly Roadmap
Weekly summary of market events and updates on our key theses.
Market Alerts ⚡️FlashInsights
Real-time market commentary about macro and crypto events from our research heads.
Real-Time
sean farrell Crypto Team

Sean Farrell & Crypto Team

Type Publication Mon Tue Wed Thu Fri Monthly
Reports Market Update
Stay on top of the crypto markets with macro commentary, technical analysis, and the most relevant news.
Weekly Strategy
Weekly summary of market events and updates on our key theses.
Funding Fridays
Are you looking for investment opportunities in the crypto space? We explore early-stage crypto opportunities in this note about where the smart money is being invested!
Crypto Concepts
We periodically provide in-depth research on the leading protocols, companies, and funds shaping the crypto ecosystem.
Liquid Ventures
A recurring research note focused on delivering unique insights into high-risk investment opportunities within the crypto ecosystem, primarily centered on early-stage or small-cap tokens.
Deep Research
We periodically provide in-depth research on the leading protocols, companies, and funds shaping the crypto ecosystem.
Quarterly
Weekly Roadmap
Weekly summary of market events and updates on our key theses.
Webinars & Videos Outlook Webinars
Ongoing webinars exploring crypto opportunities, in depth research, and exclusive research offerings from our team of analysts and leading cryptocurrency firms.
Yearly
Crypto Comments Daily Technical Strategy
From Bitcoin, Ethereum and Solana to other coins, our Head of Technical Strategy highlights important price movement to help give you an edge.
Allocation Tools Crypto Core Strategy
A powerful tool designed to help crypto investors build a crypto portfolio that outperforms the industry’s king – bitcoin – regardless of market conditions.
Market Alerts ⚡️FlashInsights
Real-time market commentary about macro and crypto events from our research heads.
Real-Time
Crypto Team

FS Insight Research Team

Type Publication Mon Tue Wed Thu Fri Monthly
Reports First to Market
*Earnings Daily
This note provides investors with a myriad of useful metrics to measure the progress of earnings season
Signal From Noise
Highlights timely market themes and sectors with corresponding stocks, cutting through the day-to-day market “noise” for a distinct perspective.
Community Questions
We gather your inquiries and answer them in the most scalable way. Hear directly from our research principals!
FS Insight Academy
Our main goal is to make you a better investor! This series will guide you through key financial concepts and topics in an understandable way.
Webinars & Videos Free Macro Webinars
Live webinars and Q&A with our research team and high-profile industry leaders.
Quarterly
Free Crypto Webinars
Live webinars and Q&A with our research team and high-profile industry leaders.
Quarterly

*Daily reporting during each quarterly earnings season.

More from the author

Disclosures (show)

Sign in to read the report!

We have detected you are an active member!

Ray: c1af67-177ca1-accd01-1bf2df-cb7efb

Want to receive Regular Market Updates to your Inbox?

I am your default error :)

Events

Trending tickers in our research